Predicting castration-resistant prostate cancer after combined androgen blockade

Miao He; Haina Liu; Jingyi Cao; Qian Wang; Haiting Xu; Yufeng Wang

doi:10.18632/oncotarget.22246

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Predicting castration-resistant prostate cancer after combined androgen blockade

Miao He, Haina Liu, Jingyi Cao, Qian Wang, Haiting Xu and Yufeng Wang _

PDF | HTML | How to cite

Oncotarget. 2017; 8:105458-105462. https://doi.org/10.18632/oncotarget.22246

Metrics: PDF 1184 views | HTML 1984 views | ?

Abstract

Miao He1, Haina Liu1, Jingyi Cao2, Qian Wang2, Haiting Xu3 and Yufeng Wang1

1Department of Nuclear Medicine, Xuzhou Cancer Hospital, Jiangsu Province, Xuzhou, China

2Department of Urology, Xuzhou Cancer Hospital, Jiangsu Province, Xuzhou, China

3Department of Radiotherapy and Oncology, Xuzhou Cancer Hospital, Jiangsu Province, Xuzhou, China

Correspondence to:

Yufeng Wang, email: [email protected]

Keywords: prostate cancer; bone metastasis; bone scan; combined androgen blockade; castration resistance

Received: March 24, 2017 Accepted: October 02, 2017 Published: November 01, 2017

ABSTRACT

This study analyzed ⁹⁹Tcm-MDP bone scans and investigated factors influencing early-stage castration resistance in prostate cancer (CRPC) patients with bone metastasis. We retrospectively analyzed clinical data from 92 patients with bone metastatic prostate cancer treated with maximal androgen blockade. Patients were imaged with ⁹⁹Tcm-MDP bone scan to detect metastases, and prostate specific antigen (PSA) values were measured regularly. Before treatment, 464 total bone metastases were detected in the 92 patients, with pelvic bone metastases accounting for about 30.6% of the total. After combined androgen blockade treatment, median CRPC occurrence time was 23 months. A longer time to reach the lowest PSA value was an independent predictor of early-onset CRPC (occurrence <1 year after treatment). Our findings suggest that ⁹⁹Tcm-MDP bone scans are useful for diagnosing prostate cancer bone metastasis and grading. Patients with Gleason scores>8, higher PSA values after treatment, and shorter times to reach the lowest PSA value had poorer responses to combined androgen blockade treatment.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 22246

Publication Alerts

Research Papers:

Predicting castration-resistant prostate cancer after combined androgen blockade

Abstract